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Abstract: The current treatment of breast cancer, the most frequent malignancy found in females, requires the 
study of biomarkers. The standard set of these includes at least an estrogen receptor, a progesterone receptor 
and a HER2 receptor, although many other factors have been shown to contribute to the prognosis. Tissue 
microarrays have been introduced to decrease costs and workload of immunohistochemistry applied to large 
collections of samples. The aim of the study was to test the performance of this technology on three basic biomar-
kers of breast carcinoma in 106 cases of invasive breast carcinoma. Tissue microarrays composed of 3 cores sized 
0.6 mm per case were constructed and stained by standard immunohistochemistry. The results were assessed on 
virtual slides created with an Aperio scanner. A sensitivity and specificity of 0.83 and 0.88 was obtained for the 
estrogen receptor, 0.76 and 0.88 for the progesterone receptor, 0.69 and 0.96 for HER2. In conclusion, TMA 
technology may give results comparable to the diagnosis based on whole sections, and the clinicopathologic 
correlations for the immunohistochemistry performed by both methods are fairy similar. (Folia Histochemica et 
Cytobiologica 2013, Vol. 51, No. 4, 326–332)
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Introduction
As the most frequent cancer occurring in females, 
breast carcinoma (BC) is a disease of an outstanding 
importance both for clinician and pathologist. Altho-
ugh the primary classification is done by standard histo-
pathology, immunohistochemistry is increasingly used 
both for classification and prognosis. The routinely 
used immunohistochemical (IHC) methods include 
determination of receptor status, namely estrogen re-
ceptor (ER), progesterone receptor (PR) and HER2. 
These define three main classes of BC: steroid receptor 
dependent (ER+, PR+, HER2–), HER2 dependent 
(ER–, PR–, HER2+) and triple negative (ER–, PR–, 
HER2–). These categories differ in their aggressiveness 
as well as treatment. Many other biomarkers were 
also shown to contribute to the prognosis, and some 
are on the way to become diagnostic standards [1–3]. 
Currently, immunohistochemistry for ER, PR and 
HER2 should be performed in every case of BC; the 
side effects in the diagnostic therapeutic improvement 
are the increased costs of histological examination. 
Tissue microarrays (TMA) are commonly used to 
reduce costs and efficacy of biomarker assessment. 
This method combines material from several tissue 
blocks into a single recipient block, reducing the costs 
and labor considerably, however, at the expense of 
lower representativeness. Some authors proposed 
the use of TMAs for routine IHC classification of BC 
while others advocated more caution in this regard 
[4–7]. Since our lab has specific experience in using the 
TMA method both for immunohistochemistry and in 
situ hybridization, we decided to test the feasibility of 
TMA assessment of receptor status in BC and compare 
them with the results obtained by routine immunohi-
stochemistry. We wanted also to see how many cases 
would be lost from the TMA assay, and how this loss 
would influence overall results of the receptor assays.
Material and methods
The material consisted of 106 unselected archival cases of 
invasive ductal breast carcinoma. The clinicopathologic 
327Tissue microarrays for receptor testing in breast carcinoma
©Polish Society for Histochemistry and Cytochemistry
Folia Histochem Cytobiol. 2013
10.5603/FHC.2013.0044
www.fhc.viamedica.pl
data is shown in Table 1. The hematoxylin and eosin stained 
slides were evaluated microscopically and the ones conta-
ining areas of best-preserved cancer tissue were chosen 
for TMA construction. The source area was marked on 
the slide, copied onto paraffin block and tissue cores 
were transferred into recipient block. The TMAs were 
constructed using MTA1 device (Beecher Instruments, 
Sun Prairie, WI, USA) (Figure 1). From each case, 3 cores 
sized 0.6 mm were extracted. From the blocks, 2µm sec-
tions were prepared and used for immunohistochemistry. 
The immunohistochemistry for ER and PR was done by 
routine manual method. Briefly, the slides were de-waxed, 
rehydrated and incubated in 3% peroxide solution for 
10 minutes to block the endogenous peroxidase activity. An-
tigen retrieval was carried out by heating in citrate buffer 
for 30 minutes. The Lab-Vision detection system was used. 
Staining for HER2 was done by automatic method using 
the Benchmark Classic device (Ventana Medical Systems, 
Tucson, AZ, USA), according to the manufacturers’ pro-
tocol. The staining results are shown on Figures 2, 3 and 
4. Primary antibodies used for the study were for estrogen 
receptor EMR02 (Leica Biosystems, Wetzlar, Germany), 
for progesterone receptor SAN27 (Leica Biosystems, 
Wetzlar, Germany) and for HER2 4B5 (Ventana Medical 
Systems, Tucson, AZ, USA).
The slides were scanned with Aperio CS device (Aperio 
Inc., Vista, CA, USA) and virtual slides visually reviewed 
and scored. For the evaluation of estrogen and progesterone 
receptors, the percentage of strongly positively stained nuclei 
was assessed. For HER2 assessment, the cores were classi-
fied into the standard categories according to ASCO/CAP 
guidelines [8]. Cases 0 and 1+ on HER2 are refferend to as 
‘negative’, cases 2+ as ‘ambigous’, and 3+ as ‘positive’. This is 
in concordance with the clinical meaning of the HER2 assay: 
in 3+ cases anti-HER2 antibodies are used for treatment, 
2+ cases require in situ hybridisation before therapy choice, 
while 0 and 1+ cases are treated by other methods. The results 
of standard (whole sections) immunohistochemistry perfor-
med manually were obtained from the department’s files. 
Statistical analysis. The statistical analysis was done using 
Excel 2010 (Microsoft, Redmond, WA, USA), Statistica 10 
(StatSoft, Tulsa, OK, USA) and QuickCalcs (GraphPad So-
ftware Inc., La Jolla, CA, USA http://graphpad.com/quick-
calcs/) programs. Pearson’s c2, Mann-Whithey U test, kappa 
statistics were used, as deemed appropriate. Bland-Altman 
analysis was performed with Statistica software with a macro 
written by Matt Coates, available from http://sdn.statsoft.
com/STATISTICAVisualBasicExamples/BlandAltmanPlot.
aspx. The correlation between variables was assessed by 
Spearman’s correlation coefficient. The significance level 
was set to P < 0.05.
Table 1. Clinicopathologic data of the cases under study
Age Mean 56.3 years (range 28 to 85, SD 14.16)
Stage No (%)
pT1a 8 (7.55%)
pT1b 53 (50%)
pT1c 41 (38.68%)
pT4b 4 (3.77%)
Lymph node status No (%)
N0 61 (57.55%)
N1mi 6 (5.66%)
N1a 26 (24.53%)
N2a 5 (4.72%)
N3a 8 (7.55%)
Grade No (%)
G1 17 (16.04%)
G2 54 (50.94%)
G3 35 (33.02)
Figure 1. One of the routine tissue microarray slides used in 
the study. Notice the asymmetric arrangement of individual 
cores, necessary for proper orientation. Also, the loss of 
some cores may be appreciated
Figure 2. Strong and uniform nuclear reactivity for proge-
sterone receptor. Original magnification 200 ×
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Results
On whole-slide immunohistochemistry which had been 
performed manually, the average percentage of ER 
positive cells was 68.61% (range 0 to 100, SD 36.65). 
The average percentage of PR positive cells was 60.45% 
(0 to 100, 39.98: range and SD, respectively). HER2 
Figure 3. Infiltrating ductal carcinoma positive for estrogen 
receptor; majority of cells are positive, yet the reaction is 
weaker than on Figure 2. Original magnification 200 ×
Figure 4. Strong reactivity for HER2 receptor. Such tumor 
is likely to show good response to HER2 targeted treat-
ment. Original magnification 200 ×
Figure 5. Bland Altman plots of the estrogen receptor 
(A), progesterone receptor (B) and HER2 (C) assessed by 
whole slides and tissue microarrays
was 0 in 11 cases (10.38%), 1+ in 53 cases (50%), 
2+ in 28 cases (26.42%), 3+ in 14 cases (13.21%). 
According to standard threshold, 16 cases 
(15.09%) were ER negative and 90 cases (84.91%) 
were ER positive; 27 cases (25.47%) were PR nega-
tive and 79 cases (74.53%) were PR positive; 64 cases 
(60.38%) were HER2-negative, 28 cases (26.42%) 
were HER2 ambiguous (requiring FISH), 14 cases 
(13.21%) were HER2-positive.
On TMA immunohistochemistry, the average 
percentage of ER positive cells was 53.56% (range 
0 to 100, SD 42.57); however, 12 (11.32%) cases were 
lost from TMA in processing. The average percenta-
ge of PR positive cells was 37.05% (range 0 to 100 
SD 41.78); 14 (13.2%) cases were lost from TMA in 
processing. HER2 was 0 in 39 cases (36.79%), 1+ in 
21 cases (19.81%), 2+ in 12 cases (11.32%), 3+ in 
9 cases (8.49%); 25 cases (23.58%) were lost from the 
TMA. According to the standard threshold, 27 cases 
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(25.47%) were ER negative and 67 cases (63.21%) 
were ER positive; 39 cases (36.79%) were PR nega-
tive and 53 cases (50%) were PR positive; 60 cases 
(56.60%) were HER2 negative, 12 cases (11.32%) 
were HER2 ambiguous (requiring FISH), 9 cases 
(8.49%) were HER2 positive.
The results of whole-slide and TMA assessment 
strongly correlated (for ER r = 0.66 P < 0.001; for 
PR r = 0.73 P < 0.001; for HER2 r = 0.62 P < 0.001). 
However, the results obtained by both methods were 
not identical. The mean difference for ER was 12.91% 
(range –68 to 100, SD 32.89), for PR 11.53% (range 
–99 to 90 SD 33.71), and for HER2 0.59% (range –1 
to 3, SD 0.8). Tables 1 to 3 and Figure 5 show the 
relationships between clinically relevant receptor 
immunoreactivities assessed in standard, manually 
stained histologic slides and TMAs. It is evident that 
use of TMA has high positive predictive value specifi-
city yet lower negative predictive value and sensitivity. 
There was no difference in number of available cores 
between concordant and discordant cases.
The ER, PR and HER2 status did not show signi-
ficant differences between pT stages, both in case of 
whole-slide and TMA immunohistochemistry (data 
not shown). As might have been expected, there was 
a statistically significant relationship between the 
grade of the tumor and receptor status: higher grade 
cancers tended to be ER and PR negative and HER2 
positive more often than the lower grade. These rela-
tionships were similar for both whole-slide and TMA 
immunohistochemistry (Figure 6).
Discussion
The study of biomarkers considerably increases the 
effectiveness of cancer prognosis and treatment. 
Often the multivariate analysis of biomarkers and 
morphologic features offers quite good discrimination 
between groups; however, in the routine diagnostic 
workup, the principal limit is the increased cost and 
workload. The tissue microarray technology, introdu-
ced in the ` 90s, permitted the analysis of several cases 
within a single tissue block [9, 10]. The advantage of 
this approach is a dramatic reduction in expenses and 
laboratory workload. In fact, a single TMA may con-
tain as many as hundreds of samples. This may result 
in a significant reduction of overall costs, especially if 
many markers are studied within a single experiment. 
IHC analysis of datasets containing thousands of cases 
is otherwise impossible or, at best, extremely difficult. 
Utilizing this method Tamini et al. [11] performed 
TMA analysis of a large cohort of over 3000 BC cases 
with sections stained for ER, PR, HER2, CK5/6 and 
EGFR. These authors used 3 0.6 mm cores for each 
Table 3. Progesterone receptor positive and negative re-
sults assessed by two methods
TMA
Negative Positive
Whole slides Negative 23 3
Positive 16 50
Positive predictive value 0.94
Negative predictive value 0.59
Sensitivity 0.76
Specificity 0.88
Kappa 0.56
case and reported to have used 23 TMA blocks. This re-
sults in a total of only 115 slides stained (23 × 5 = 115), 
while with standard technology, 15465 slides (3093 × 5 = 
= 15465) would be stained, a workload that would 
be prohibitive. As the result, the authors were able 
to reproduce molecular classification of the BC 
cases. Similarly, Callagy et al. [12] successfully used 
TMA immunohistochemistry for emulating mole-
cular classification of breast cancer. TMAs may 
also be used for in situ hybridization studies [13].
Several choices have to be made before starting 
a TMA experiment. A principal one is the size of the 
array itself and the diameter of individual cores. The 
core size may range from 0.5 to 3 mm and 0.6 mm was 
applied in our study; while the arrays with smallest 
cores contain hundreds of cases, the ones with largest 
cores will consist of a few dozen samples only.
Despite its obvious advantages TMA technology 
suffers from some drawbacks. The principal one is 
the limited size of the core examined. A single core 
contains only a small fraction of the entire section 
which, by itself, represents only a small fraction of an 
Table 2. Estrogen receptor positive and negative results 
assessed by two methods
 
 
TMA
Negative Positive
Whole slides Negative 14 2
Positive 13 65
Positive predictive value 0.97
Negative predictive value 0.52
Sensitivity 0.83
Specificity 0.88
Kappa 0.56
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entire lesion. Thus, TMAs are most useful for detec-
ting markers with a diffuse and uniform expression 
within a lesion. Although this technique may be less 
adequate for analyzing parameters which, by their 
nature, vary between various tumor tissue regions 
differing in microvessel density or tumor-related 
inflammatory infiltrate, we used it successfully for 
microvessel analysis [14]. Early and in situ lesions 
may be particularly difficult to be properly inc-
luded in the TMAs [15]. Further progress may be 
obtained with TMA technology via integration with 
imaging systems, allowing computer-aided array 
design and scoring based on image-analysis. With 
this methodology, the possibility arises to choose 
cores from specific compartments, e.g. inside of the 
lesion, infiltration front, perilesional inflammatory 
infiltrate, etc. [16]. However, by using such appro-
ach, non-trivial problems will be encountered like 
separation of neoplastic from non-neoplastic cells, 
exclusion of poorly preserved tissue, and overlapping 
nuclei. Some of these problems may be solved using 
semiautomatic, human–manned systems. Unfortuna-
tely, this will limit the profits of automated analysis. 
Faratian et al. [17] have validated the uses of image 
analysis system for the evaluation of steroid recep-
tors in breast cancer; they found that a sufficient 
accuracy may be obtained with just two cores and an 
excellent accuracy with six cores. Additionally, the 
use of virtual slides technology, like in the present 
study, may help the manual assessment. Another 
drawback of the TMA technique is the tissue core 
loss. Inevitably, even in experienced hands, some 
tissue cores may contain no tumor and others may be 
positioned outside the plane of section. Furthermo-
re, during the staining procedure, especially during 
antigen retrieval, some of the cores are lost. To limit 
the influence of tissue loss the usual procedure is to 
include several cores from a single case which limits 
the advantages of the technology. On the other hand, 
Figure 6. The relationship between tumor grade and receptors expression. Whole slides (left) and TMAs (right) are 
shown in the same scale
Table 4. HER2 receptor positive and negative results asses-
sed by two methods
 
 
TMA
Ambiguous* Positive
Whole 
slides
Negative 2 0
Ambiguous* 9 0
Positive 1 9
Positive predictive value 1.00
Negative predictive value 0.73 
Sensitivity 0.69 
Specificity 0.96 
Kappa 0.55
* 1+ result, requiring FISH for therapy planning
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including several cores makes TMA more represen-
tative of the entire case. 
Although the TMAs have been used for more than 
15 years, the optimal number of cores has yet not 
been standardized, and various authors may propose 
different solutions. E.g. Camp et al. [18] validated 
the use of TMAs for BC. They demonstrated that 
just two 0.6 mm TMA cores are sufficient for proper 
assessment of hormonal and HER2 receptors. Zang 
et al. [19] analyzed the results of TMA assessment of 
HER2 in breast cancer; they used only one 0.6 core 
per case and reported high accuracy of the method. 
Highest discordance rates were seen for 2+ staining 
cases. According to these authors 2+ cases should 
be reevaluated using immunohistochemistry and 
FISH on whole slides [19]. Graham et al. [20] also 
advocated for the practical application of TMA for 
HER2 evaluation in BC, yet reported that 5 cores 
were needed for proper assessment of the marker and 
obtained extremely good (> 95%) agreement between 
whole slides and TMAs. Kyndi et al. [21] analyzed the 
problem of staining heterogeneity encountered by 
including TMA cores from different paraffin blocks 
and different parts of the block. They reported very 
significant concordance of the results for a single 
breast tumor and concluded that a single core was 
sufficient for consistent evaluation. Conversely, Lin 
et al. [7] concluded that TMA concordance with stan-
dard immunohistochemistry strongly depended on 
the number of cores studied. The ranges of specificity 
and sensitivity seen by Lin et al. were similar to those 
found in our study. Lin et al. concluded that TMA 
should be used for biomarker research, however cau-
tion is advised when applying this technology for the 
purposes of diagnostic pathology. On a small series 
of cases, Awadelkarim et al. [5] by comparing TMAs 
with classical IHC evaluation reported for TMAs 
sensitivities of 77.8%, 82.8%, 83.3%, and negative 
predictive values of 64.7%, 72.2%, 96.4% for ER, 
PR and HER2, respectively. Their results were thus 
similar to ours but no relationship was found between 
the tumor size and TMA accuracy in our material.
TMAs were also extensively used for quality 
assurance and control, facilitating the process of the 
same staining on several tissues, allowing for the 
identification of discrepancies. Thus, in Wasielewski 
et al. study [22] tumors with more ambiguous staining 
results tended to show higher inter-observer and in-
ter-laboratory variability. Diaz et al. [23] specifically 
tested the feasibility of TMAs for validation of HER2 
FISH test. In this setting, the tissue microarrays were 
stained in different laboratories and the results were 
compared. These authors reported a perfect concor-
dance in all the informative cases. Programs of quality 
control on TMAs have been also introduced in Poland 
for the validation of HER2 FISH test (External Qu-
ality Assessment Scheme, run by Abbott Molecular).
In conclusion, we showed that tissue microarray 
technology may provide results comparable to whole 
sections in assessing receptor immunohistochemistry 
of breast carcinoma. The positive results were highly 
consistent, yet negative predictive value was not 
entirely satisfactory. Nevertheless, the relationship 
between clinicopathologic data and immunohisto-
chemistry performed on whole slides and TMAs were 
found to be fairy similar. 
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